Dark chocolate may have blood pressure (BP)-lowering properties due to its high content of plant-derived flavanols. 1 A metaanalysis of 10 randomized studies examining the effect of cocoa products (mostly dark chocolate) on BP reported mean pooled systolic and diastolic BP reductions of 4.5 and 2.5 mm Hg as compared to control substances containing no or only negligible amounts of flavanols. 2 Most of these studies used high doses of chocolate of up to 105 g/day for limited time periods (maximum of 15 days in 7 out of 10 trials) in healthy normotensive adults or patients with stage 1 hypertension. An obvious concern with high doses of dark chocolate is the significant energy, fat, and sugar content potentially leading to adverse metabolic effects when ingested chronically. Therefore, one trial of lowdose dark chocolate ingestion (6.3 g/day relating to an energy intake of only 30 kcal/day) over a longer time period (18 weeks) is of particular interest. 3 The study found a reduction in systolic BP of 2.9 mm Hg and diastolic BP of 1.9 mm Hg compared to flavanol-free white chocolate. No adverse metabolic effects or weight gain were observed suggesting a role of low-dose dark chocolate in the long-term treatment of hypertension. We hypothesized that the presumed antihypertensive effect of flavanol-rich dark chocolate might be more pronounced with higher doses (yet still moderate enough for a potential longterm ingestion). Apart from the question of dose dependency, only minimal data is available on the effect of dark chocolate in patients with established vascular disease or diabetes mellitus who might potentially benefit most from any vasculoprotective effects of dark chocolate.
Dark chocolate may have blood pressure (BP)-lowering properties due to its high content of plant-derived flavanols. 1 A metaanalysis of 10 randomized studies examining the effect of cocoa products (mostly dark chocolate) on BP reported mean pooled systolic and diastolic BP reductions of 4.5 and 2.5 mm Hg as compared to control substances containing no or only negligible amounts of flavanols. 2 Most of these studies used high doses of chocolate of up to 105 g/day for limited time periods (maximum of 15 days in 7 out of 10 trials) in healthy normotensive adults or patients with stage 1 hypertension. An obvious concern with high doses of dark chocolate is the significant energy, fat, and sugar content potentially leading to adverse metabolic effects when ingested chronically. Therefore, one trial of lowdose dark chocolate ingestion (6.3 g/day relating to an energy intake of only 30 kcal/day) over a longer time period (18 weeks) is of particular interest. 3 The study found a reduction in systolic BP of 2.9 mm Hg and diastolic BP of 1.9 mm Hg compared to flavanol-free white chocolate. No adverse metabolic effects or weight gain were observed suggesting a role of low-dose dark chocolate in the long-term treatment of hypertension. We hypothesized that the presumed antihypertensive effect of flavanol-rich dark chocolate might be more pronounced with higher doses (yet still moderate enough for a potential longterm ingestion). Apart from the question of dose dependency, only minimal data is available on the effect of dark chocolate in patients with established vascular disease or diabetes mellitus who might potentially benefit most from any vasculoprotective effects of dark chocolate.
The aim of our study, therefore, was to examine the dose dependency of the presumed antihypertensive effect of dark chocolate by directly comparing the BP-lowering capacity of low vs. higher doses of dark chocolate over the course of 3 months. Furthermore, given the scarce data in high-risk patients, we exclusively enrolled patients with cardiovascular end-organ damage and/or diabetes mellitus.
Methods
Design overview. Consecutive patients of either sex referred to the University of Leipzig -Heart Center (Leipzig, Germany), were invited to participate if (i) mean systolic BP on 24-h ambulatory blood pressure measurement (ABPM) was between 125 to 146 mm Hg or 80 to 89 mm Hg for diastolic BP Background Dark chocolate may have blood pressure-lowering properties. We conducted a prospective randomized open-label blinded end-point design trial to study a potential dose dependency of the presumed antihypertensive effect of dark chocolate by directly comparing low vs. higher doses of dark chocolate over the course of 3 months.
We enrolled a total of 102 patients with prehypertension/stage 1 hypertension and established cardiovascular end-organ damage or diabetes mellitus. Patients were randomly assigned to receive either 6 or 25 g/day of flavanol-rich dark chocolate for 3 months. The difference in 24-h mean blood pressure between groups was defined as the primary outcome measure.
results
Significant reductions in mean ambulatory 24-h blood pressure were observed between baseline and follow-up in both groups original contributions Dark Chocolate and Blood Pressure and (ii) patients were considered at high risk of cardiovascular events defined by one or more of the following features: angiographic evidence of coronary artery disease, peripheral arterial disease, carotid stenosis ≥50% or diabetes mellitus type I or II. The BP ranges were selected on the basis of the categories high-normal and grade 1 hypertension as recommended for office BP measurements by current guidelines. 4 ABPM readings are usually several mm Hg lower than office BP measurements. Therefore, the threshold values were slightly adjusted: High-normal BP was defined as systolic values between 125 and 134 mm Hg or diastolic values between 80 and 84 mm Hg. The corresponding ranges for grade 1 hypertension were 135-146 mm Hg and 85-89 mm Hg. 5 Exclusion criteria included regular consumption of dark chocolate or cocoa products, uncontrolled hypertension (24-h systolic BP ≥147 mm Hg or diastolic BP ≥90 mm Hg), change in BP medication in the 6 weeks preceding planned randomization, pregnancy, uncontrolled diabetes mellitus (glycosilated hemoglobin >9%) or acute disorders in glucose metabolism, tobacco smoking within the past 5 years, participation in another trial and severe comorbidities such as malignancy.
Randomization and interventions.
Potentially eligible patients willing to take part in the study underwent ABPM. If the predefined BP criteria were met, participants were randomly assigned to either 6 or 25 g/day of commercially available dark chocolate (Ritter Sport Halbbitter; Alfred Ritter GmbH & Co. KG, Waldenbuch, Germany) for 3 months (after a cocoa-free run-in period of 1 week). The dark chocolate product had been used in several trials before. 3, [6] [7] [8] Nutrient composition including flavanol content has been described in detail. 3 Of note, the 6 g dose (25 g dose) corresponded to a daily intake of 5 (21) mg of monomeric epicatechin (a flavanol subcompound), 1.7 (7.1) g of fat, 3.4 (14.2) g of carbohydrates, 0.3 (1.3) g of protein, and a total energy content of 30 (125) kcal. The 6 g dose was chosen because of its efficacy in lowering BP in a previous trial. 3 The 25 g dose was selected on the basis of a presumably more pronounced antihypertensive effect compared to 6 g/day and because it was considered the upper limit of what could be ingested on a chronic basis without adverse effects on metabolic parameters and patient compliance.
Eligible patients were assigned to the treatment groups by permuted block randomization with the entire sample treated as one block using a computer-generated list of random numbers. To conceal allocation from the investigators involved, the chocolate doses for each patient were packed in identicallooking, sequentially numbered, opaque and sealed containers. The randomization list was generated and maintained by a physician not involved in the clinical conduct of the study. Randomization data were kept strictly confidential until completion of the study. All investigators were blinded to treatment assignment. Patients could not be blinded to the intervention because of the obvious difference in quantitative intake of dark chocolate between the groups. All participants were instructed that disclosure of treatment group to clinical investigators would result in exclusion from the study.
Patients were instructed to ingest the chocolate 2 h after the last meal in the evening as described previously. 3 Participants were instructed to maintain their usual diet but refrain from flavanol-rich foods and beverages. All patients received dietary counseling at the start of the study and received a detailed list of food items to avoid.
Pre-existing BP medication remained unchanged at study entry. Patients and general practitioners involved were asked not to alter BP medication during the study period.
ABPM was performed using a validated oscillometric device (Spacelabs model 90207; Spacelabs Healthcare GmbH, Feucht, Germany). 9 The initial ABPM readings were compared with those from a sphygmomanometer to check that the differences were no more than ±5 mm Hg. BP was recorded at 30-min intervals throughout the 24-h recording period. The daytimeinterval was set between 7:00 am and 10:00 pm and the nighttime interval between 10:00 pm and 7:00 am, respectively. Quality criteria included (i) a minimum of 75% valid readings and (ii) no more than two consecutive hours of missing data. If these criteria were not met, patients were asked to repeat measurements within the next 3 days. If the repeat study failed to meet the quality control, the ABPM was considered nonevaluable and the patient excluded from analysis. Mean arterial pressure (MAP) was measured directly by the oscillometric device at the maximum amplitude of oscillations. Systolic and diastolic BP were then determined in relation to the maximum amplitude according to the internal device algorithm. Systolic pressure was set at the rise of the curve when oscillations reach 50% of maximum amplitude. Diastolic pressure was set at the fall of the curve when oscillations reach 75% of maximum amplitude. Body weight was obtained (with patients in underwear, in a fasted state, and after bladder emptying) using a medical scale (Tanita HD-317), zeroed and calibrated before each measurement.
The protocol was approved by the local institutional review board and conducted in accordance with the principles of the Declaration of Helsinki. All subjects gave written informed consent before enrollment.
Outcomes and follow-up. The primary objectives of the study were (i) to assess whether a reduction in 24-h MAP can be detected between baseline and follow-up in the intervention groups and (ii) whether a difference between the two groups with regard to a change in 24-h MAP can be detected. The difference in 24-h MAP between groups at follow-up was defined as the primary efficacy end point. The main secondary end point was defined as the change in 24-h MAP from baseline to follow-up in the treatment groups. Additional analyses were carried out on systolic and diastolic BP responses and circadian BP patterns. Furthermore, the BP effects were examined by quartiles of baseline 24-h MAP. At day 1 (baseline) and 
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Dark Chocolate and Blood Pressure 3 months (follow-up) patients were clinically examined and blood samples were obtained. A telephone interview was conducted 4 weeks after enrollment to assess compliance, change in dietary habits, and adverse effects.
Statistical analysis. Sample size was calculated for the betweengroup comparison. The calculation was based on a difference of 3 mm Hg in 24-h MAP at follow-up between groups. On the basis of pooled data from previous trials we assumed a s.d. of 5 mm Hg. 3, 7, 8, 10, 11 Thus, 43 patients per treatment arm needed to be analyzed to reject the null hypothesis of equal means between the two groups to provide a statistical power of 80%. To account for potential dropouts, 51 patients were randomized in each arm.
To assess between-group differences, BP changes between baseline and follow-up were calculated and compared using a two-tailed independent samples t-test. Furthermore, analysis of covariance was carried out to compare final between-group differences in 24-h MAP, systolic and diastolic BP values to adjust for potential baseline imbalances. For within-group comparisons the differences between the related baseline and follow-up measurements were calculated and analyzed using a one-sample t-test. Baseline characteristics were compared using a χ 2 -test for categorical variables and an independent samples t-test for continuous data with normal distribution. Otherwise the nonparametric Wilcoxon rank-sum test was used. Categorical variables are expressed as number and percentage of patients. Continuous data are reported as means and s.d. as well as 95% confidence intervals when appropriate. A P value <0.05 was considered statistically significant. Statistical analyses were performed with SPSS 17.0 (SPSS, Chicago, IL).
results

Patient characteristics
Between February 2008 and January 2009, 163 patients eligible by clinical criteria were screened by ABPM (Figure 1) . Table 1 .
Apart from a larger proportion of male patients in the 25 g/day group, no significant differences could be detected between the two treatment arms. Of note, antihypertensive medication at study entry was similar between groups. At the time of enrollment in the trial, all except one patient (99%) received at least one antihypertensive agent, and 93% were taking two or more classes of antihypertensive medications. Ninety-one patients completed the trial. Reasons for discontinuation of the study or noninclusion in the final analysis are shown in Figure 1 .
Comedication remained unchanged in all subjects.
Blood pressure
At study entry, high-normal BP and grade 1 hypertension (as defined above) was diagnosed in 63 and 37% of patients, respectively. Baseline and post-treatment BP values are shown in Table 2 . Significant reductions in mean and systolic 24-h BP were observed between baseline and follow-up in both groups (Figure 2) . Diastolic 24-h BP was reduced in both groups as well, however this was statistically significant in the 6 g/day group only. We recorded decreases in daytime BP in both groups. Reductions in nighttime BP were less pronounced with marginally significant results for participants ingesting the lower chocolate dose and nonsignificant reductions for the higher-dose group. The changes in BP at 3 months by quartiles of baseline 24-h MAP are shown in Table 3 . We recorded significant reductions in BP in patients with medium and higher pretreatment values whereas no significant reduction was seen in patients with low baseline BP readings. No significant differences between the two groups could be found for 24-h MAP (primary end point), 24-h systolic or diastolic BP and daytime and nighttime BP readings ( Table 2) . The between-group results for 24-h MAP, systolic and diastolic BP did not change when adjusted for baseline imbalances by analysis of covariance.
safety, tolerability, and serum markers
Both doses of dark chocolate were generally well-tolerated. Obstipation was reported by one patient in the 6 g/day group and by three patients in the 25 g/day group (leading to study discontinuation in one participant). According to the results of direct questioning, analyses of patient diaries and return of empty containers, all chocolate portions were consumed in the 91 patients analyzed. None of the patients reported changes in dietary habits. During follow-up, body weight remained unchanged in the lower-dose group. In the higher-dose group, however, a slight increase in body weight was noted (0.8 kg, 95% confidence interval 0.06 to 1.6, P = 0.03). No changes in glucose metabolism, as assessed by fasting glucose, were observed between and within groups. Low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, and high-sensitivity C-reactive protein remained unchanged. discussion This is the first study to directly compare the presumed antihypertensive effect of different doses of dark chocolate and the largest randomized trial to date addressing the potential effect of flavanol-rich dark chocolate on BP as the primary objective. Furthermore, the trial exclusively enrolled patients with established cardiovascular end-organ damage and/or 
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Dark Chocolate and Blood Pressure diabetes mellitus. Only minimal data on the potential effect of dark chocolate on BP has been available in these patients who are at the highest risk for cardiovascular events and might therefore benefit most from BP-lowering measures. The major findings are: (i) significant reductions in 24-h MAP over the course of 3 months were recorded for both intervention groups (flavanol-rich dark chocolate at doses of 6 and 25 g/day); (ii) no significant differences in BP changes were observed between groups (primary study end point); and (iii) a slight increase in body weight was noted in participants ingesting the higher dose of 25 g/day.
The BP reductions seen in the present study of patients with established cardiovascular disease and/or diabetes mellitus study are similar to those observed in a previous trial of prehypertension and stage 1 hypertension patients ingesting 6 g/ day of dark chocolate. 3 Several mechanisms responsible for the presumed BP-lowering effect of dark chocolate have been described. An increase in vasodilating nitric oxide bioavailability possibly caused in part by an enhanced nitric oxide synthase activity is considered a potential pathway. 3, [12] [13] [14] Other mechanisms such as the inhibition of angiotensin-converting enzyme activity by flavanols may also play a role. 15 A limitation of clinical trials using dark chocolate is the lack of an adequate control substance. To date, there is no commercially available flavanol-free chocolate that offers the distinct bitter taste and dark color inherent to cocoa-rich chocolate. White chocolate has been used as a comparator in several trials. 2 However, informed consent requires that patients be instructed on the lack of beneficial health effects of white chocolate precluding the definition of a placebo. Indeed, given the fact that participants are aware of its nonexisting health actions, white chocolate might not even be considered as a neutral control substance but could be termed a "negative placebo. " Although hypothetical, this might even explain some of the effects seen in previous trials comparing dark and white chocolate. We therefore decided not to include a white chocolate control arm. Instead, we tried to minimize the placebo phenomenon by using ABPM in a "Prospective Randomized Open-Label Blinded Endpoints" (PROBE) design. ABPM has repeatedly been shown not to be associated with a significant placebo effect in short-term trials lasting up to 12 weeks. 16 Furthermore, there is evidence that changes in mean ABPM from PROBE trials and from double-blind, placebo-controlled trials are statistically equivalent, where equivalence is defined as ruling out a difference of ≥3 mm Hg in the change from baseline in systolic BP and ≥2 mm Hg in diastolic BP. 17 Apart from a true antihypertensive effect of dark chocolate, regression to the mean might also be responsible for the observed BP reductions. Regression to the mean refers to the phenomenon that individuals with BP values above the population mean on the first measurement tend to display lower readings in a second measurement. Unfortunately, due to the lack of a control group, we cannot separate regression to the mean from any genuine intervention effect in the present analysis. The fact that BP reductions were mainly confined to patients with high pretreatment values supports the possibility of regression to the mean effects.
The increase in body weight seen with the 25 g/day intake warrants caution with the chronic ingestion of moderate or high doses of dark chocolate. Because weight increases are associated with a rise in BP, this might counteract potential antihypertensive effects of dark chocolate. 18, 19 Although previous trials using higher doses of dark chocolate did not report significant changes in body weight, this is likely explained by their short follow-up duration. 2 Although all patients received dietary counseling at the start of the study and were given a list of high-flavanol foods to avoid, we did not undertake a detailed assessment of dietary habits. Therefore, we cannot rule out imbalances between groups with regard to flavanol intake from food sources other than cocoa products. However, given the sample size of over 90 patients and the randomized design, this seems unlikely.
In conclusion, our results are consistent with the hypothesis that dark chocolate may be associated with a reduction in BP. However, due to the lack of a control group, confounding may be possible and the results should be interpreted with caution. Low doses of flavanol-rich dark chocolate could easily be incorporated into a normal diet and thus hold promise as part of an overall approach to lower cardiovascular risk. However, before dark chocolate can be recommended as a treatment option in hypertension, a large-scale, well-controlled trial preferably with clinical end points is needed.
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